S-Nitrosogluthione reductase inhibitor / N6022 is a potent and reversible inhibitor of S-nitrosoglutathione reductase (GSNOR) – IC50 = 20 nM1, 8 nM2. It demonstrated significant efficacy in a mouse models of ovalbumin-induced asthma, chronic obstructive pulmonary disease, and irritable bowel syndrome. N6022 was able to attenuate experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis) via selective inhibition of pro-inflammatory CD4+ cells (TH1/TH17) while upregulating anti-inflammatory subsets of CD4+ cells (TH2/Treg) without causing lymphopenia.3
Biochemicals & reagents
1208315-24-5
1) Sun et al. (2011), Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases; ACS Med. Chem. Lett. 2 402 2) Green et al. (2012), Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase; Biochemistry 51 2157 3) Saxena et al. (20198), S-Nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis; Free Radic. Biol. Med. 121 57
-20°C
TARGET: Glutathione -- PATHWAY: Redox -- RESEARCH AREA: Immunology -- DISEASE AREA: Inflammation